Paras Healthcare IPO: Comprehensive Review, Dates, Financials, and Valuation Analysis
The primary market continues to experience active momentum with new corporate offerings entering the exchange ecosystem. Among the prominent upcoming ventures, the initial public offering from a major healthcare platform has garnered significant interest from market participants. This comprehensive analysis breaks down the essential parameters, core operations, financial trajectory, and valuation metrics of the offering to assist market participants in navigating their investment strategy effectively.
Key Offer Highlights
- Total Issue Size: ₹1,450.00 Crores
- Price Band: ₹660 to ₹693 per equity share
- Lot Size: 21 Shares
- Listing Exchanges: BSE and NSE
Corporate Overview: What the Enterprise Does
Established decades ago, the organization has evolved into a premier clinical specialty-led hospital network delivering robust tertiary and quaternary medical services across North India, Bihar, and Jharkhand. Operating under a recognized brand umbrella, the network features multiple hospitals equipped with modern medical infrastructure.
The enterprise focuses heavily on high-acuity medical disciplines including cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics, sports injury management, and renal specialties. These specialized segments drive the majority of the organization's core revenues, reflecting strong clinical expertise and high-value patient care delivery.
Offering Schedule and Timeline
Understanding the operational timeline is crucial for proper fund allocation and bidding execution. Below is the structured roadmap tracking the offering from the opening date through the final exchange listing.
| Event Milestone | Associated Date | Progress Status |
|---|---|---|
| Bidding Opening Date | October 21, 2026 | |
| Bidding Closing Date | October 23, 2026 | |
| Allotment Finalization | October 26, 2026 | |
| Refund Initiation & Demat Credit | October 27, 2026 | |
| Tentative Listing Date | October 28, 2026 |
Detailed Offering Structure & Lot Size
The aggregate issue size reaches ₹1,450 crores, structured carefully through a combination of a fresh capital issuance and an offer for sale component by existing stakeholders. Retail investors can participate by bidding for a minimum baseline lot.
| Investor Category | Minimum Lots | Shares Required | Minimum Investment (₹) |
|---|---|---|---|
| Retail (Minimum) | 1 | 21 | ₹14,553 |
| Retail (Maximum) | 13 | 273 | ₹1,89,189 |
| Small HNI (Minimum) | 14 | 294 | ₹2,03,742 |
Corporate Financial Performance
A thorough examination of restated consolidated financials reveals substantial top-line growth and progressive recovery in bottom-line profitability over recent fiscal periods.
| Financial Metric (₹ in Crores) | Period Ended Jun 2026 | FY Ended Mar 2026 | FY Ended Mar 2025 |
|---|---|---|---|
| Total Assets | 2,202.88 | 2,071.14 | 1,810.45 |
| Total Income | 478.75 | 1,628.78 | 1,314.21 |
| Profit After Tax (PAT) | 49.68 | 43.83 | -57.98 |
| EBITDA | 113.48 | 335.58 | 156.46 |
| Net Worth | 444.96 | 394.94 | 280.49 |
Primary Objectives of the Issue
The enterprise intends to deploy the net proceeds derived from the fresh issuance strategically toward strengthening its balance sheet and supporting expansion initiatives:
- Prepayment or scheduled repayment, in full or part, of certain outstanding borrowings availed by the company.
- Investment in the wholly-owned subsidiary for the repayment or prepayment of specific corporate debt.
- General corporate requirements and operational contingencies.
Promoter Shareholding & Selling Stakeholders
The enterprise is promoted by experienced healthcare management professionals. Prior to the offering, promoters hold a dominant stake in the organization. The Offer for Sale (OFS) component involves stake dilution from specific corporate bodies and promoter entities, ensuring compliance with public float regulations.
SWOT Strategic Evaluation
Strengths
- Strong regional leadership across targeted geographic clusters.
- Established operational track record with a balanced network of hospitals.
- High concentration of revenues driven by advanced clinical specialties.
Weaknesses
- High capital intensity associated with hospital infrastructure scaling.
- Geographic concentration risks centered primarily around northern states.
Opportunities
- Expansion pipeline aimed at increasing overall bed capacity significantly by upcoming fiscal years.
- Growing demand for specialized tertiary medical care in tier-two cities.
Threats
- Intense competition from established domestic healthcare chains.
- Regulatory shifts concerning medical pricing and healthcare policies.
Corporate Contact & Registrar Information
For official correspondence, inquiries, or grievance management regarding allotment status and application tracking, stakeholders can connect through the designated channels:
- Registrar: MUFG Intime India Private Limited
- Lead Managers: Managed by prominent financial institutions including JM Financial Ltd and advisory partners.
- Corporate Headquarters: Gurugram, Haryana, India.
Final Summary
The offering presents a compelling opportunity for market participants looking to gain exposure to the growing healthcare sector in India. With solid expansion blueprints and improving financial metrics, careful evaluation of individual risk appetite and financial goals is advised before committing capital.